NCT05627245 2026-04-22
Testing the Safety of the Anti-cancer Drugs Tazemetostat and Belinostat in Patients With Lymphomas That Have Resisted Treatment
National Cancer Institute (NCI)
Phase 1 Active not recruiting
Clinical Trials
29 trialsNCT04224493 2026-04-20
SYMPHONY-1
Ipsen
Phase 3 Active not recruiting
NCT05983965 2026-04-17
Study of Tazemetostat in Lymphoid Malignancies
University of Alabama at Birmingham
Phase 1 Terminated
NCT03155620 2026-04-14
Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT03213665 2026-04-13
Tazemetostat in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With EZH2, SMARCB1, or SMARCA4 Gene Mutations (A Pediatric MATCH Treatment Trial)
National Cancer Institute (NCI)
Phase 2 Completed
NCT06824701 2026-04-06
TARZAN
University of Utah
Phase 1 Suspended
NCT05618366 2026-04-02
Tazemetostat and Venetoclax in Relapsed/Refractory Non-Hodgkin Lymphoma
Weill Medical College of Cornell University
Phase 1 Terminated
NCT05994235 2026-04-02
Tazemetostat and Mosunetuzumab in Untreated Follicular Lymphoma
Weill Medical College of Cornell University
Phase 2 Active not recruiting
NCT06242834 2026-04-01
Pembrolizumab and Tazemetostat to Overcome Immune Tolerance Following ASCT or CAR T-cell Therapy in Patients With Aggressive B-Cell Non-Hodgkin's Lymphoma
Northwestern University
Phase 2 Active not recruiting
NCT06692452 2026-04-01
Tazemetostat Plus CHOP in 1L T-cell Lymphoma
Dana-Farber Cancer Institute
Phase 2 Withdrawn
NCT05551936 2026-02-17
A Study of Tazemetostat With Rituximab and Abbreviated Bendamustine in the Frontline Treatment of High Tumor Burden Follicular Lymphoma
Big Ten Cancer Research Consortium
Phase 1/2 Active not recruiting
NCT06068881 2026-01-30
Mandolin
Ipsen
Phase 2 Withdrawn
NCT06575686 2026-01-21
Epcoritamab and Tazemetostat for the Treatment of Relapsed or Refractory Grade I-IIIa Follicular Lymphoma
City of Hope Medical Center
Phase 2 Suspended
NCT02875548 2025-11-04
TRuST
Ipsen
Phase 1/2 Completed
NCT05890352 2025-10-20
Study Adding Drugs to Usual Treatment for Large B-Cell Lymphoma That Returned or Did Not Respond to Treatment
SWOG Cancer Research Network
Phase 2 Recruiting
NCT07209163 2025-10-06
Combination Therapy With Tazemetostat in Relapsed and Refractory Peripheral T-cell Lymphoma
Ruijin Hospital
Phase 1/2 Not yet recruiting
NCT05934838 2025-08-15
A Feasibility Trial of Tazemetostat Plus CAR T Cell Therapy in B-cell Lymphomas
Weill Medical College of Cornell University
Phase 1 Recruiting
NCT04537715 2025-02-19
Effects of Itraconazole and Rifampin on the Blood Tazemetostat Levels
Ipsen
Phase 1 Completed
NCT05713110 2025-01-22
A Study of Tazemetostat in Combination With HMPL-689 in Patients With Relapsed/Refractory Lymphoma
Hutchmed
Phase 2 Completed
NCT02889523 2024-10-09
Epi-RCHOP
The Lymphoma Academic Research Organisation
Phase 1/2 Active not recruiting
NCT01897571 2024-03-26
Study of Tazemetostat as Single Agent in Solid Tumors or B-cell Lymphomas and in Combination With Prednisolone in DLBCL
Ipsen
Phase 1/2 Completed
NCT04762160 2024-03-25
SYMPHONY-2, A Trial to Examine Combination of Tazemetostat With Rituximab in Subjects With Relapsed/Refractory Follicular Lymphoma
Ipsen
Phase 2 Terminated
NCT03010982 2024-03-22
Open-Label, Multi-Center, Two-Part, Ph1 Study to Characterize the PKs of an Intravenous Micro-Dose of [14C]-Tazemetostat (EPZ 6438) and the ADME of an Oral [14C]-Labeled Dose of Tazemetostat in Subjects With B-Cell Lymphomas or Adv Solid Tumors
Ipsen
Phase 1 Completed
NCT05604417 2023-07-07
Zandelisib + Tazemetostat in R/R Follicular Lymphoma
Massachusetts General Hospital
Phase 1/2 Withdrawn
NCT03028103 2023-06-26
Open-Label, Multicenter, Two-Part, Phase 1 Study to Characterize Effects of a Moderate CYP3A Inhibitor on PK of Tazemetostat, Effects of Tazemetostat on PK of CYP2C8 and CYP2C19 Substrates, and Effect of Increased Gastric pH on PK of Tazemetostat in B-cell Lymphoma or Advanced Solid Tumor Patients
Ipsen
Phase 1 Completed
NCT05152459 2023-05-31
Tazemetostat in Combination With Umbralisib and Ublituximab for the Treatment Relapsed or Refractory Follicular Lymphoma
City of Hope Medical Center
Phase 1/2 Withdrawn
NCT03456726 2022-12-16
Study of Tazemetostat in Participants With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma With EZH2 Gene Mutation
Eisai Inc.
Phase 2 Completed
NCT03009344 2022-11-10
A Study of Tazemetostat in Participants With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma
Eisai Inc.
Phase 1 Completed
NCT02220842 2020-01-27
A Safety and Pharmacology Study of Atezolizumab (MPDL3280A) Administered With Obinutuzumab or Tazemetostat in Participants With Relapsed/Refractory Follicular Lymphoma and Diffuse Large B-cell Lymphoma
Hoffmann-La Roche
Phase 1 Completed